Evidence map›Paper›PMID 38924359›Full record

ArticleJournal of the International AIDS Society2024

Factors associated with PrEP-era HIV seroconversion in a 4-year U.S. national cohort of n = 6059 sexual and gender minority individuals who have sex with men, 2017-2022.

Christian Grov, Yan Guo, Drew A Westmoreland, Alexa B D'Angelo, Chloe Mirzayi, Michelle Dearolf, Pedro Carneiro, Meredith Ray, David Pantalone, Adam W Carrico and 5 more

Abstract read
In one paragraph

Article in Journal of the International AIDS Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. AnbioRxiv : the preprint server for biology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Christian GrovCity University of New York (CUNY) Graduate School of Public Health and Health Policy, New York City, New York, USA.ORCID 0000-0001-6871-3531
Yan GuoCity University of New York (CUNY) Graduate School of Public Health and Health Policy, New York City, New York, USA.
Drew A WestmorelandUniversity of Florida, Gainesville, Florida, USA.
Alexa B D'AngeloCity University of New York (CUNY) Graduate School of Public Health and Health Policy, New York City, New York, USA.
Chloe MirzayiCity University of New York (CUNY) Graduate School of Public Health and Health Policy, New York City, New York, USA.
Michelle DearolfCity University of New York (CUNY) Graduate School of Public Health and Health Policy, New York City, New York, USA.
Pedro CarneiroCity University of New York (CUNY) Graduate School of Public Health and Health Policy, New York City, New York, USA.ORCID 0000-0002-4638-7824
Meredith RayUniversity of Memphis, Memphis, Tennessee, USA.
David PantaloneUniversity of Massachusetts Boston, Boston, Massachusetts, USA.
Adam W CarricoFlorida International University, Miami, Florida, USA.
Viraj V PatelAlbert Einstein College of Medicine, Bronx, New York, USA.ORCID 0000-0002-5603-9823
Sarit A GolubHunter College of CUNY, New York City, New York, USA.
Sabina HirshfieldState University of New York (SUNY) Downstate, Brooklyn, New York, USA.
Donald R HooverRutgers University, New Brunswick, New Jersey, USA.
Denis NashCity University of New York (CUNY) Graduate School of Public Health and Health Policy, New York City, New York, USA.

Funding

Patient and Population Health Outcomes Research SWGP30AI124414 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Kathryn M. Anastos · 2017 to 2026
$28.3M
Following a U.S. National Cohort of Vulnerable Men to Improve HIV Prevention and CareUH3AI133675 · NIAID · GRADUATE SCHOOL OF PUBLIC HEALTH AND HEALTH POLICY · PI GROV, CHRISTIAN · 2019 to 2021
$6.9M
National Institute of Allergy and Infectious Diseases K01 AA 029047National Institute of Allergy and Infectious Diseases UH3 AI 133675NIAID NIH HHS P30 AI124414NIH HHS UH3 AI 133675
6 · The paper itself

Abstract

introductionCommunity-based cohort studies of HIV seroconversion can identify important avenues for enhancing HIV prevention efforts in the era of pre-exposure prophylaxis (PrEP). Within individuals, one can assess exposure and outcome variables repeatedly and with increased certainty regarding temporal ordering. This cohort study examined the association of several risk factors with subsequent HIV seroconversion.

methodsWe report data from a 4-year study (2017-2022) of 6059 HIV seronegative sexual and gender minority individuals who have sex with men who had indications for-, but were not using-, PrEP at enrolment. Participants completed repeat exposure assessments and self-collection of biospecimens for HIV testing. We examined the roles of race and ethnicity, socio-economic status, methamphetamine use and PrEP uptake over the course of follow-up in relation to HIV seroconversion.

resultsOver 4 years, 303 of the participants seroconverted across 18,421 person-years (incidence rate = 1.64 [95% CI: 1.59-1.70] per 100 person-years). In multivariable discrete-time survival analysis, factors independently associated with elevated HIV seroconversion risk included being Black/African American (adjusted risk ratio [aRR]: 2.44, 1.79-3.28), Hispanic/Latinx (1.53, 1.19-1.96), housing instability (1.58, 1.22-2.05) and past year methamphetamine use (3.82, 2.74-5.33). Conversely, time since study enrolment (24 vs. 12 months, 0.67, 0.51-0.87; 36 months, 0.60, 0.45-0.80; 48 months, 0.48, 0.35-0.66) and higher education (master's degree or higher vs. less than or equal to high school, 0.36, 0.17-0.66) were associated with reduced seroconversion risk. Compared to non-PrEP users in the past 2 years without a current clinical indication, those who started PrEP but then discontinued had higher seroconversion risk, irrespective of clinical indication (3.23, 1.74-6.46) or lack thereof (4.30, 1.85-9.88). However, those who initiated PrEP in the past year (0.14, 0.04-0.39) or persistently used PrEP in the past 2 years (0.33, 0.14-0.74) had a lower risk of seroconversion. Of all HIV seroconversions observed during follow-up assessments (12, 24, 36 and 48 months), methamphetamine was reported in the 12 months prior 128 (42.2%) times (overall).

conclusionsInterventions that acknowledge race and ethnicity, economic variables such as education and housing instability, and methamphetamine use are critically needed. Not only are interventions to engage individuals in PrEP care needed, but those that retain them, and re-engage those who may fall out of care are essential, given the exceptionally high risk of seroconversion in these groups.

Indexed as

HIV InfectionsHIV SeropositivityHomosexuality, MalePre-Exposure ProphylaxisSexual and Gender MinoritiesAdolescentAdultCohort StudiesFemaleHumansMaleMiddle AgedRisk FactorsSeroconversionUnited StatesYoung AdultHIV seroconversionmethamphetaminepre‐exposure prophylaxisrace and ethnicitysexual and gender minority individualssocio‐economic status

Identifiers

PMID38924359
PMCPMC11197961

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.